Search Results - "Martini, J F"

Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations by Solomon, B.J., Martini, J.-F., Ou, S.-H.I., Chiari, R., Soo, R.A., Bearz, A., Li, S., Thurm, H., Lin, C.-C., Riely, G.J., Bauer, T.M., Shaw, A.T.

Get full text

Actomyosin contraction at the cell rear drives nuclear translocation in migrating cortical interneurons by Martini, Francisco J, Valdeolmillos, Miguel

“…Neuronal migration is a complex process requiring the coordinated interaction of cytoskeletal components and regulated by calcium signaling among other…”
Get full text

Migration of cortical interneurons relies on branched leading process dynamics by Valiente, M., Martini, F.J.

“…Migrating cells typically reach their targets in response to a relatively wide variety of extracellular molecules. Somehow surprisingly, most cells transduce…”
Get full text

Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues by TOURAINE, P, MARTINI, J.-F, KELLY, P. A, ZAFRANI, B, DURAND, J.-C, LABAILLE, F, MALET, C, NICOLAS, A, TRIVIN, C, POSTEL-VINAY, M.-C, KUTTENN, F

“…The role of PRL in human breast tumorigenesis is not well understood. One of the limitations is the difficulty of accurately measuring PRL receptors (PRLR) in…”
Get full text

Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1-/- mice by BENTZIEN, Frauke, STRUMAN, Ingrid, MARTINI, Jean-Francois, MARTIAL, Joseph, WEINER, Richard

“…The M(r) 16,000 NH(2)-terminal fragment of human prolactin (16K hPRL) is a potent antiangiogenic factor inhibiting endothelial cell function in vitro and…”
Get full text

genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC) by Ravaud, A., Motzer, R.J., Pandha, H.S., Staehler, M., George, D., Pantuck, A.J., Patel, A., Chang, Y.-H., Escudier, B., Donskov, F., Magheli, A., Carteni, G., Laguerre, B., Tomczak, P., Breza, J., Gerletti, P., Lin, X., Lechuga, M., Martini, J.-F., Patard, J.-J.

Get full text

Ischemic preconditioning attenuates ischemia/reperfusion-induced activation of caspases and subsequent cleavage of poly(ADP-ribose) polymerase in rat hearts in vivo by PIOT, C. A, MARTINI, J.-F, BUI, S. K, WOLFE, C. L

“…Recently, we have demonstrated that ischemic preconditioning (IP) both limits infarct size and decreases internucleosomal DNA fragmentation in rat hearts in…”
Get full text

Quantitative analysis by polymerase chain reaction of growth hormone receptor gene expression in human liver and muscle by Martini, J F, Villares, S M, Nagano, M, Delehaye-Zervas, M C, Eymard, B, Kelly, P A, Postel-Vinay, M C

“…A single form of GH receptor (GHR) messenger RNA (mRNA) of 4.5 kilobases, encoding the full-length GHR, has been found in man. To measure the absolute number…”
Get more information

The D152H mutation found in growth hormone insensitivity syndrome impairs expression and function of human growth hormone receptor but is silent in rat receptor by Esposito, N, Wojcik, J, Chomilier, J, Martini, JF, Kelly, PA, Finidori, J, Postel-Vinay, MC

“…In two patients with growth hormone (GH) insensitivity syndrome (Laron syndrome), in whom the GH receptor is able to bind the hormone, the D152H mutation was…”
Get full text

The Antiangiogenic Factor 16K PRL Induces Programmed Cell Death in Endothelial Cells by Caspase Activation by Martini, Jean-François, Piot, Christophe, Humeau, Laurent M, Struman, Ingrid, Martial, Joseph A, Weiner, Richard I

“…We asked whether the antiangiogenic action of 16K human PRL (hPRL), in addition to blocking mitogen-induced vascular endothelial cell proliferation, involved…”
Get full text

Localization of growth hormone receptor messenger RNA in human tissues by Mertani, H C, Delehaye-Zervas, M C, Martini, J F, Postel-Vinay, M C, Morel, G

“…In order to identify GH target cells in human tissues, we investigated the celiuiar distribution of human GH receptor (GHR) messenger RNA. This was performed…”
Get full text

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy by Ravaud, Alain, Motzer, Robert J, Pandha, Hardev S, George, Daniel J, Pantuck, Allan J, Patel, Anup, Chang, Yen-Hwa, Escudier, Bernard, Donskov, Frede, Magheli, Ahmed, Carteni, Giacomo, Laguerre, Brigitte, Tomczak, Piotr, Breza, Jan, Gerletti, Paola, Lechuga, Mariajose, Lin, Xun, Martini, Jean-Francois, Ramaswamy, Krishnan, Casey, Michelle, Staehler, Michael, Patard, Jean-Jacques

“…In patients with renal-cell carcinoma at high risk for relapse after nephrectomy, the rate of disease-free survival was significantly higher among those…”
Get full text

1976TiP A multi-national study of treatment resistance following anti-cancer therapy (TRANSLATE) by Helissey, C., Di Simone, C., Nasurdi, C., Martini, J-F., Thall, A., Cossons, N., Ho, S.

Get full text

16K Human Prolactin Inhibits Vascular Endothelial Growth Factor-Induced Activation of Ras in Capillary Endothelial Cells by D'Angelo, Gisela, Martini, Jean-François, Iiri, Taroh, Fantl, Wendy J, Martial, Joseph, Weiner, Richard I

“…Signaling pathways mediating the antiangiogenic action of 16K human (h)PRL include inhibition of vascular endothelial growth factor (VEGF)-induced activation…”
Get full text

1008P Resistance mechanisms to lorlatinib or crizotinib in treatment-naive patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) by Felip, E., Martini, J-F., Mazieres, J., Kim, D-W., Shepard, D., Polli, A., Liu, G., de Marinis, F., Toffalorio, F., Goto, Y., Solomon, B.

Get full text

Role of the cAMP Signaling Pathway in the Regulation of Gonadotropin-Releasing Hormone Secretion in GT1 Cells by Vitalis, Elizabeth A., Costantin, James L., Tsai, Pei-San, Sakakibara, Hideya, Paruthiyil, Sreenivasan, Iiri, Taroh, Martini, Jean-Francois, Taga, Michiyoshi, Amy L. H. Choi, Charles, Andrew C., Weiner, Richard I.

“…We studied the signaling pathways coupling gonadotropin-releasing hormone (GnRH) secretion to elevations in cAMP levels in the GT1 GnRH-secreting neuronal cell…”
Get full text

1196P Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) by Solomon, B.J., Martini, J-F., Bearz, A., Tan, E.H., Soo, R., Besse, B., Bauer, T.M., Shepard, D., Toffalorio, F., Abbattista, A., Felip, E., Shaw, A.T., Viteri, S., Camidge, D.R., Seto, T., Ou, S-H.I.

Get full text

906PDPhase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses by Ravaud, A, Martini, J-F, Ching, K, Staehler, M, Magheli, A, Escudier, B, Mu, X J, Valota, O, Lin, X, Motzer, R J

“…Abstract Background In the S-TRAC trial, adjuvant sunitinib (SU) prolonged disease-free survival (DFS) versus placebo (PBO) in patients (pts) with…”
Get full text

Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses by Ravaud, A., Martini, J.-F., Ching, K., Staehler, M., Magheli, A., Escudier, B., Mu, X.J., Valota, O., Lin, X., Motzer, R.J.

Get full text

906PD - Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses by Ravaud, A., Martini, J.-F., Ching, K., Staehler, M., Magheli, A., Escudier, B., Mu, X.J., Valota, O., Lin, X., Motzer, R.J.

“…In the S-TRAC trial, adjuvant sunitinib (SU) prolonged disease-free survival (DFS) versus placebo (PBO) in patients (pts) with loco-regional renal cell…”
Get full text